Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer

Clin Cancer Res. 2021 Feb 15;27(4):908-910. doi: 10.1158/1078-0432.CCR-20-4069. Epub 2020 Dec 16.

Abstract

Combination immunotherapy is an expanding therapeutic modality in hepatocellular carcinoma (HCC), a disease where single-agent immunotherapy has failed to lead to survival benefit. The RESCUE trial adds camrelizumab and apatinib to the therapeutic armamentarium of advanced HCC, raising questions around the optimal positioning of various combination regimens in liver cancer.See related article by Xu et al., p. 1003.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Hepatocellular* / drug therapy
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / drug therapy
  • Programmed Cell Death 1 Receptor / therapeutic use

Substances

  • Programmed Cell Death 1 Receptor